Skip to main content
. 2022 Dec 18;14:17588359221139678. doi: 10.1177/17588359221139678

Figure 3.

Figure 3.

Univariate and multivariate Cox-proportional hazards model for OS of patients receiving CDK4/6i.

CDK4/6i, cyclin-dependent kinase 4/6 inhibitor; OS, overall survival.